Product: Alcon’s Clareon family of intraocular lenses (IOLs).
Top Line: Alcon (SIX/NYSE: ALC) this week announced the launch of the Clareon family of intraocular lenses (IOLs) in the U.S. Utilizing Alcon’s most advanced IOL material, Clareon can deliver consistent visual outcomes and exceptional clarity that lasts. The Clareon clarity is born out of a glistening-free IOL material that has among the lowest levels of haze and subsurface nanoglistenings (SSNGs) compared to leading competitor IOLs, the announcement noted.
Clareon Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the U.S., according to the Alcon announcement on Monday. Clareon PanOptix offers patients the possibility of 20/20 vision at distance (far), intermediate (at arm’s length) and near (up close), with continuous vision of 20/25 or better. Clareon Vivity is a non-diffractive extended depth of focus lens with wavefront-shaping X-WAVE technology, delivering monofocal-quality distance with excellent intermediate and functional near vision and with a monofocal visual disturbance profile.
Clareon Toric will be available in the U.S. later this year, the company said. Alcon will be rolling out the Clareon family of IOLs in international markets throughout 2022 and 2023.
Close Up: “We are proud to offer our latest IOL technology in the U.S. and other countries across the globe. At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients,” said Ian Bell, President, Global Business & Innovation, Alcon. “Clareon is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems—to deliver exceptional, long-lasting clarity.”
The Clareon portfolio leverages many of the same design characteristics and optics as Alcon’s leading IOLs to help deliver the outcomes surgeons expect. Clareon offers sharp, crisp vision with a proprietary edge designed to help reduce glare and posterior capsular opacification. The lens’ unique and proven Stableforce Haptics provide superior axial and rotational stability.
Clareon has been extensively researched, with inclusion in 30 published studies worldwide. Clareon Monofocal and Clareon Toric IOLs have already been implanted in more than 1 million eyes across more than 70 countries. 
Vital Stats: Clareon IOLs are inserted using the next-generation, reusable Clareon Monarch IVDelivery System, which provides precise and controlled implantation and that was designed specifically for the new Clareon material. Clareon Monofocal is also available in the next-generation automated, single-use delivery system, AutonoMe.
www.alcon.com